Crown Equity Holdings Inc., (CRWE)
Voice over Internet Protocol or VoIP technology is capable of cutting costs in telecommunications as well as improving the productivity of a business.
VoIP service technology quality has really come a long way since its original inception. VoIP may have been extremely limited in the past, but this no longer the case. Today's Voice over IP services have evolved significantly, allowing for you to make calls and receive calls using not only standard phones but also IP phones, which are rich in unique features. The sound quality has also vastly improved to the point where many companies have abandoned their traditional telephone systems in favor of the VoIP service.
Crown Equity Holdings Inc. (CRWE.OB) www.crownequityholdings.com announced that its subsidiary Crown Tele Services Inc. has entered into a letter of intent with MVOX AG.
MVOX AG, located in Germany, will work with Crown Tele Services Inc. www.crownteleservices.com as a technological partner in offering wireless broadband solutions (wireless carrier class infrastructure in high speed data and WiMAX).
MVOX AG offers wireless broadband internet access services with over 15 years of experience as a system integrator, as well as being the most successful WiMAX operator in Germany. The company is based in Garching a.d. Alz, Germany.
Commenting on the Letter of Intent, "The keystone of our business has always been our commitment to meeting our customers' network needs and we will continue to grow with this principle," said Kenneth Bosket, Crown Tele Services Inc., President and CEO.
Crown Tele Services Inc. is a provider of affordable, world class (VoIP) communications solutions and is a subsidiary of Crown Equity Holdings Inc. For more information visit www.crownteleservices.com.
Crown Equity Holdings Inc. offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. Its advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.
For more information, visit http://www.crownequityholdings.com
*********************************************
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), announced its results for the fourth quarter and year ended December 31, 2011. At December 31, 2011, the Company had cash, cash equivalents, interest receivable, and investment securities of $39.5 million, as compared to $28.5 million at December 31, 2010. The net loss for the fourth quarter ended December 31, 2011 was $8.4 million, or $0.12 per share, compared to a net loss of $5.3 million, or $0.09 per share, for the comparable quarter in 2010, representing an increase in net loss of $3.1 million. The change in net loss in the fourth quarter of 2011, as compared to the fourth quarter of 2010, was primarily attributable to a $2.5 million increase in other research and development expenses, principally related to the KRX-0401 (perifosine) and Zerenex Phase 3 clinical programs. The net loss for the fourth quarter ended December 31, 2011, included $0.5 million of non-cash compensation expense related to equity incentive grants.
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment cancer and renal disease.
*********************************************
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced it will release financial results for the fourth quarter and full year ended December 31, 2011, after the market closes on Thursday, March 8, 2012, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.
Zogenix, Inc., a pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain.
*********************************************
Alimera Sciences, Inc. (Nasdaq:ALIM) a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Dan Myers, president and chief executive officer, will present at the 32nd Annual Cowen & Company Health Care Conference at 10:40 A.M. ET on Wednesday, March 7, 2012 in Boston, MA. The presentation will be webcast live and can be accessed on the Investor Relations section of the corporate website at http://www.alimerasciences.com. For those who are not available to listen to the live broadcast, the webcast will be archived for 90 days.
Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina.
Sign up for free stock alerts at http://www.pennygovernance.com/signup
***************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyGovernance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyGovernance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.(read more @ http://pennygovernance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.